CD305 antibody | NKTA255
Mouse anti Human CD305:Alexa Fluor® 647
Mouse anti Human CD305:FITC
Mouse anti Human CD305
- Product Type
- Monoclonal Antibody
- Clone
- NKTA255
- Isotype
- IgG1
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| MCA2242A647 | F | 100 Tests/1ml | ||||
| MCA2242F | F | 0.1 mg | ||||
| MCA2242GA | F IP WB | 0.1 mg | ||||
| MCA2242 | F IP WB | 0.2 mg |
Mouse anti Human CD305 antibody, clone NKTA255 recognizes human leukocyte-associated Ig-like receptor-1 (LAIR-1), a ~40 kDa cell surface molecule that functions as an inhibitory receptor on natural killer cells, monocytes and T cells. LAIR-1, otherwise known as CD305, is also expressed by other hematopoietic cells including B cells, but is not expressed by non-haematopoietic, platelets or erythrocytes.
Mouse anti Human CD305 antibody, clone NKTA255 is reported to inhibit NK cell triggering via CD16 molecules (Poggi et al. 1995).
Mouse anti Human CD305 antibody, clone NKTA255 is reported to inhibit NK cell triggering via CD16 molecules (Poggi et al. 1995).
Product Details
- Target Species
- Human
- Product Form
- Purified IgG conjugated to Alexa Fluor 647 - liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Carrier Free
- Yes
- Immunogen
- NK cell lines B12.100 and AM.25
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised mice were fused with cells of the P3U1 myeloma cell line
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 12 months from date of despatch
- Shelf Life
- 18 months from date of despatch.
- Shelf Life
- 18 months from date of despatch.
More Information
- UniProt
- Q6GTX8 Related reagents
- Entrez Gene
- LAIR1 Related reagents
- GO Terms
- GO:0005886 plasma membrane
- GO:0005515 protein binding
- GO:0016021 integral to membrane
- GO:0004872 receptor activity
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Regulatory
- For research purposes only
Applications of CD305 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | 1/50 | 1/100 | |
| Immunoprecipitation | |||
| Western Blotting |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Western Blotting
- MCA2242 detects a band of approximately 40 kDa (1).
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse IgG1 Negative Control:Alexa Fluor® 647 | MCA928A647 | 100 Tests/1ml | F | ||
| Mouse IgG1 Negative Control:FITC | MCA928F | 100 Tests | F | ||
| Mouse IgG1 Negative Control | MCA928 | 100 Tests | F |
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Human Seroblock | BUF070A | 50 Test | F | ||
| Human Seroblock | BUF070B | 200 Test | F | ||
| Human Seroblock | BUF070A | 50 Test | F | ||
| Human Seroblock | BUF070B | 200 Test | F |
Product Specific References
Source Reference
-
Poggi, A. et al. (1995) p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans.
Eur J Immunol. 25 (2): 369-76.
References for CD305 antibody
-
Poggi, A. et al. (2000) Engagement of the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias.
Eur J Immunol. 30 (10): 2751-8. -
Zocchi, M.R. et al. (2001) Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells.
Eur J Immunol. 31 (12): 3667-75. -
Poggi, A. et al. (1997) p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes.
Int Immunol. 9 (9): 1271-9. -
Poggi, A. et al. (2008) Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division.
Leukemia. 22 (5): 980-8.
